{"id":52939,"date":"2023-01-16T14:02:22","date_gmt":"2023-01-16T13:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/"},"modified":"2023-01-16T14:02:22","modified_gmt":"2023-01-16T13:02:22","slug":"global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/","title":{"rendered":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Peripheral Neuropathy Clinical Trial Pipeline Highlights – 2022”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis report provides the most up-to-date information on key pipeline products within the global Peripheral Neuropathy market. It covers emerging therapies for Peripheral Neuropathy in active clinical development stages including early and late stage clinical trials.\n<\/p>\n

\nThe pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.\n<\/p>\n

\nClinical Trial Stages:<\/strong>\n<\/p>\n

\nThe report provides Peripheral Neuropathy pipeline products by clinical trial stages including both early and late stage development – phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.\n<\/p>\n

\nDrug Mechanism Classes:<\/strong>\n<\/p>\n

\nThe report provides Peripheral Neuropathy pipeline products by their dominant mechanism of action\/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.\n<\/p>\n

\nCompany:<\/strong>\n<\/p>\n

\nThe report provides Peripheral Neuropathy pipeline products by the company.\n<\/p>\n

\nShort-term Launch Highlights:<\/strong>\n<\/p>\n

\nFind out which Peripheral Neuropathy pipeline products will be launched in the US and Ex-US till 2025.\n<\/p>\n

\nKey Topics Covered:<\/strong>\n<\/p>\n

\n1. Peripheral Neuropathy Pipeline by Stages\n<\/p>\n

\n2. Peripheral Neuropathy Phase 3 Clinical Trial Insights\n<\/p>\n

\n3. Peripheral Neuropathy Phase 2 Clinical Trial Insights\n<\/p>\n

\n4. Peripheral Neuropathy Phase 1 Clinical Trial Insights\n<\/p>\n

\n5. Peripheral Neuropathy Preclinical Research Insights\n<\/p>\n

\n6. Peripheral Neuropathy Discovery Stage Insights\n<\/p>\n

\n7. Appendix\n<\/p>\n

\n8. Research Methodology\n<\/p>\n

\nFor more information about this report visit https:\/\/www.researchandmarkets.com\/r\/xsr8t7<\/a>\n<\/p>\n

\nAbout ResearchAndMarkets.com<\/strong>\n<\/p>\n

\nResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nResearchAndMarkets.com
\n
Laura Wood, Senior Press Manager
\n
press@researchandmarkets.com<\/a>
For E.S.T Office Hours Call 1-917-300-0470
\n
For U.S.\/ CAN Toll Free Call 1-800-526-8630
\n
For GMT Office Hours Call +353-1-416-8900\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DUBLIN–(BUSINESS WIRE)–The “Global Peripheral Neuropathy Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline products within the global Peripheral Neuropathy market. It covers emerging therapies for Peripheral Neuropathy in active clinical development stages including early and late stage clinical trials. The … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52939","6":"format-standard","7":"category-industry"},"yoast_head":"\nGlobal Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DUBLIN–(BUSINESS WIRE)–The “Global Peripheral Neuropathy Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline products within the global Peripheral Neuropathy market. It covers emerging therapies for Peripheral Neuropathy in active clinical development stages including early and late stage clinical trials. The ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-16T13:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 – ResearchAndMarkets.com\",\"datePublished\":\"2023-01-16T13:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/\"},\"wordCount\":330,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005309\\\/en\\\/1686487\\\/21\\\/logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/\",\"name\":\"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005309\\\/en\\\/1686487\\\/21\\\/logo.jpg\",\"datePublished\":\"2023-01-16T13:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005309\\\/en\\\/1686487\\\/21\\\/logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230116005309\\\/en\\\/1686487\\\/21\\\/logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 – ResearchAndMarkets.com\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/","og_locale":"en_US","og_type":"article","og_title":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend","og_description":"DUBLIN–(BUSINESS WIRE)–The “Global Peripheral Neuropathy Clinical Trial Pipeline Highlights – 2022” report has been added to ResearchAndMarkets.com’s offering. This report provides the most up-to-date information on key pipeline products within the global Peripheral Neuropathy market. It covers emerging therapies for Peripheral Neuropathy in active clinical development stages including early and late stage clinical trials. The ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-16T13:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 – ResearchAndMarkets.com","datePublished":"2023-01-16T13:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/"},"wordCount":330,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/","url":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/","name":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 - ResearchAndMarkets.com - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg","datePublished":"2023-01-16T13:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230116005309\/en\/1686487\/21\/logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/global-peripheral-neuropathy-clinical-trial-pipeline-highlights-2022-researchandmarkets-com\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Global Peripheral Neuropathy Clinical Trial Pipeline Highlights 2022 – ResearchAndMarkets.com"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52939","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52939"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52939\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52939"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52939"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52939"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}